Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P40616
UPID:
ARL1_HUMAN
Alternative names:
-
Alternative UPACC:
P40616; B4DWW1; P80417; Q53XB1
Background:
ADP-ribosylation factor-like protein 1 is a pivotal GTP-binding protein, orchestrating a myriad of cellular processes by recruiting effectors such as golgins, arfaptins, and Arf-GEFs to the trans-Golgi network. It modulates functions at the Golgi complex, influencing cell polarity, innate immunity, and protein secretion. Notably, arfaptins contribute to maintaining insulin secretion from pancreatic beta cells, highlighting the protein's broad impact on cellular physiology.
Therapeutic significance:
Understanding the role of ADP-ribosylation factor-like protein 1 could open doors to potential therapeutic strategies.